Evolent Begin Period Cash Flow from 2010 to 2025
| EVH Stock | USD 9.45 0.12 1.29% |
Begin Period Cash Flow | First Reported 2014-03-31 | Previous Quarter 137.9 M | Current Value 127.9 M | Quarterly Volatility 96.7 M |
Check Evolent Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evolent Health's main balance sheet or income statement drivers, such as Depreciation And Amortization of 124.3 M, Total Revenue of 2.7 B or Gross Profit of 226.2 M, as well as many indicators such as Price To Sales Ratio of 0.48, Dividend Yield of 0.0163 or PTB Ratio of 1.35. Evolent financial statements analysis is a perfect complement when working with Evolent Health Valuation or Volatility modules.
Evolent | Begin Period Cash Flow |
Latest Evolent Health's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Evolent Health over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Evolent Health's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evolent Health's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Evolent Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 178,892,262 | |
| Geometric Mean | 107,107,467 | |
| Coefficient Of Variation | 71.03 | |
| Mean Deviation | 102,143,295 | |
| Median | 170,029,000 | |
| Standard Deviation | 127,062,053 | |
| Sample Variance | 16144.8T | |
| Range | 383.1M | |
| R-Value | 0.74 | |
| Mean Square Error | 7753.1T | |
| R-Squared | 0.55 | |
| Significance | 0.001 | |
| Slope | 19,824,854 | |
| Total Sum of Squares | 242171.5T |
Evolent Begin Period Cash Flow History
About Evolent Health Financial Statements
Investors use fundamental indicators, such as Evolent Health's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Evolent Health's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 223.5 M | 230.6 M |
Currently Active Assets on Macroaxis
When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:Check out the analysis of Evolent Health Correlation against competitors. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 0.163 | Return On Assets | Return On Equity |
The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolent Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.